Report from the extraordinary general meeting in Orexo AB, 6 August 2013
The extraordinary general meeting resolved on 6 August on amendment to Performance-based, Long-term Incentive Program 2011/2021, issue of warrants with the right to subscribe for new shares and approval of disposal of the warrants.
For more information regarding the resolutions at the extraordinary general meeting reference is made to the complete proposal which is available on the company’s webpage.
For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: + 46-703 50 78 88, Email: email@example.com
Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue-generating US and EU approved products currently marketed under license and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharmaceutical companies. Orexo, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.
For information about Orexo AB please visit www.orexo.com.
Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 16:45 CET on August 6, 2013.